News
- December 17, 2018
- Asahi Kasei Pharma to solicit proposals for drug discovery research
- December 11, 2018
- Asahi Kasei Pharma launches Kevzara® autoinjector for treatment of rheumatoid arthritis
- December 3, 2018
- Addition of Kevzara® to category of drugs subject to guidance and management fee for self-injection at home and lift of ban on long-term prescription
- October 30, 2018
- Application for approval to manufacture and sell Teribone™ autoinjector
- August 2, 2018
- Preliminary results of overseas Phase III clinical study for ART-123
- July 24, 2018
- Asahi Kasei Pharma signs distribution agreement with Stanbio Laboratory for the marketing of Lucica® Glycated Albumin-L in the US
- March 26, 2018
- License agreement for novel P2X7 receptor antagonist
- February 5, 2018
- Asahi Kasei Pharma launched Kevzara® Subcutaneous Injection, a treatment for rheumatoid arthritis, in Japan
Page Top
Copyright © Asahi Kasei Pharma Corporation. All Rights Reserved.